Is the Shingles Vaccine Worthwhile? What You Should Know

For most adults over 50, the shingles vaccine is one of the clearest wins in preventive medicine. The recombinant vaccine Shingrix prevents roughly 85% of shingles cases across a wide age range, with even stronger protection against the disease’s most feared complication, a chronic nerve pain condition that can last months or years. The picture does get more nuanced when you factor in side effects, cost, and how long protection lasts, but the core evidence is unusually strong for an adult vaccine.

What Makes Shingles Worth Vaccinating Against

Shingles is caused by varicella-zoster virus, the same virus behind chickenpox. After a childhood chickenpox infection, the virus doesn’t leave your body. It retreats into nerve cells along the spine and skull, where it can sit dormant for decades.¹ When immune surveillance weakens, whether from aging, stress, illness, or medications, the virus can reactivate and travel along a nerve to the skin, producing the painful, blistering rash of shingles.

The numbers are not trivial. About a third of people who had chickenpox will develop shingles at some point, and the United States sees over a million cases per year.² Risk climbs steeply with age. For women aged 45, the remaining lifetime risk sits around 32%; for men the same age, about 22%.³ By age 80, the annual incidence reaches roughly 10 cases per 1,000 people, which means that in any given year, about 1 in 100 people in that age group will get shingles.²

The rash itself is miserable but temporary. The real concern is what can follow. Up to about 20% of people with shingles develop postherpetic neuralgia, or PHN, a condition where pain persists at the site of the rash for months or even years after the rash has healed.⁴ PHN involves several types of pain, including constant burning, stabbing episodes, and extreme sensitivity to light touch. For older adults, it can disrupt sleep, daily functioning, and overall quality of life for a long time.⁵ Shingles can also affect the eye when the virus reactivates along a facial nerve, a complication called zoster ophthalmicus that can threaten vision.

How Effective Shingrix Actually Is

Shingrix is a two-dose vaccine, with the second shot given two to six months after the first.⁶ Unlike the older live vaccine Zostavax, which used a weakened form of the virus and has since been discontinued in the U.S., Shingrix is a recombinant vaccine. It contains a single protein from the virus’s surface combined with a purpose-built immune booster called an adjuvant.⁷ Because it doesn’t contain live virus, it’s safe for people whose immune systems are compromised, a group that couldn’t receive Zostavax at all.⁸

In a large real-world study of U.S. adults aged 50 and older, the two-dose series was about 86% effective at preventing shingles overall. Among those 50 to 79, effectiveness was close to 87%. Even in adults 80 and older, where immune responses are generally weaker, effectiveness held at about 80%.⁹ In the original clinical trials, protection faded only minimally over four years and remained strong in people 70 and older.¹⁰

Where the vaccine really earns its reputation is in preventing the worst outcomes. A study looking at PHN specifically found that full vaccination cut the risk by 87%. Even partial vaccination, meaning only one dose, reduced PHN risk by about 69%. During the first two years after vaccination, effectiveness against PHN exceeded 90%. By the third year and beyond, it had dipped to around 77%, still substantial.¹¹ And among people who got shingles despite being vaccinated, their risk of developing PHN was still about 47% lower than it was for unvaccinated people who got shingles. In other words, even when the vaccine doesn’t prevent the rash, it appears to reduce the severity enough to lower the chance of that dreaded chronic pain.

The Side Effect Question

If you ask people why they haven’t gotten the vaccine, or why they got only the first dose, side effects come up more than any other concern. Shingrix is genuinely more reactogenic than most vaccines adults are used to. The adjuvant that makes it so effective also triggers a strong immune response that many people feel. Injection site pain is almost universal, and fatigue is extremely common.¹² Many recipients also report muscle aches, headache, and sometimes a day or two of feeling wiped out. These reactions typically resolve within two to three days.

The trouble is that the intensity of these short-term side effects creates a real barrier. In a Michigan-based study, nearly half of unvaccinated adults said they were concerned about tolerability, and those concerns translated directly into behavior. People worried about side effects were roughly 1.2 times more likely to skip the vaccine entirely, and almost twice as likely to get only one dose instead of completing the series.¹³ Among people who had actually completed both doses, only about 22% reported being concerned about tolerability, suggesting the experience is usually less bad than the anticipation.

There’s an important distinction between tolerability and safety here. Feeling lousy for a day is a tolerability issue. Serious adverse events, the kind that land you in a hospital or cause lasting harm, are a safety issue. In clinical trials, the rates of serious adverse events in people receiving Shingrix were not meaningfully different from people receiving a placebo.¹⁴ The vaccine has a good safety profile. It just doesn’t have a pleasant one.

Getting Both Doses Matters

Because Shingrix requires two doses, a meaningful number of people never finish the series. Forgetfulness, scheduling hassles, the memory of side effects from the first shot, and cost all play a role.¹⁵ The recommended window for the second dose is two to six months after the first, and completing the series within that window is what produces the immune response the vaccine was designed for.⁶

A single dose still provides partial protection. As noted above, one dose reduced PHN risk by about 69%, compared with 87% for the full series.¹¹ So if you’ve gotten one dose and life got in the way, the first shot wasn’t wasted. But you’re leaving a significant chunk of protection on the table. If more than six months have passed, current guidance generally says to get the second dose anyway rather than restarting the series.

What About People with Weakened Immune Systems

People on immunosuppressive medications, cancer patients, organ transplant recipients, and those living with HIV are at substantially higher risk of shingles. They’re also the group that couldn’t receive the older live vaccine. Shingrix’s non-live design opened the door, and the evidence so far is encouraging. A meta-analysis across immunocompromised populations found that the vaccine reduced shingles incidence by about 81% compared to placebo.¹⁴

The effectiveness does vary by condition. In stem cell transplant recipients aged 18 to 49, vaccine efficacy was about 72%, and in those 50 and older, around 67%. In people with blood cancers, efficacy was estimated at roughly 87%.¹² Transplant recipients and people with a history of cancer tended to mount weaker immune responses than other immunocompromised groups. Side effects were more common in vaccine recipients than placebo, but serious adverse events were not.¹⁴

People on corticosteroids are a particularly common group with questions about this vaccine. In a study looking at PHN specifically, people who had been on corticosteroids before vaccination still saw 75% effectiveness against PHN, compared to 88% for those who hadn’t been on steroids.¹¹ Less than ideal, but still highly worthwhile given their elevated baseline risk.

Is It Cost-Effective

This is where things get more nuanced, and age matters. The two-dose series runs around $280 to $350 total. Most private insurance and Medicare Part D cover the vaccine, though copays vary and out-of-pocket costs are one of the most cited barriers to completion.¹⁵

From a health-economics perspective, Shingrix is clearly cost-effective for adults 60 and older. A recent analysis found that the cost per quality-adjusted life year gained was about $31,000 at age 60, roughly $16,000 at age 70, and about $19,000 at age 80, all well below the $100,000-per-QALY threshold that economists generally use to define good value.¹⁶ For adults vaccinated right at age 50, the math was less favorable, with a cost of about $161,000 per QALY. The analysis found that vaccination became cost-effective at approximately age 54. Compared to the old live vaccine, Shingrix is both more effective and less expensive when evaluated head-to-head.¹⁷

The economics are most sensitive to three factors: vaccine price, how common shingles is in the age group being vaccinated, and how long the protection lasts. Because shingles incidence rises sharply with age, vaccinating at 60 or 65 squeezes more value from each dose than vaccinating at 50, even though younger adults mount stronger immune responses. That said, the U.S. recommendation to start at 50 reflects a broader judgment that the disease burden in the 50-to-54 group is still meaningful, especially given individual variation in risk.

Possible Benefits Beyond Shingles Prevention

Some of the most intriguing recent findings about Shingrix have nothing to do with rashes or nerve pain. Several large observational studies have linked the vaccine to lower risks of cardiovascular disease and dementia, though the mechanisms behind these associations are still being investigated.

On the cardiovascular side, a study tracking vaccinated and unvaccinated adults over five years found that vaccinated individuals had lower rates of both heart attack and stroke, with the strongest benefit appearing in people with diabetes, where the odds of stroke and heart attack were each reduced by roughly 35 to 37%.¹⁸ A separate analysis looking at cardiovascular burden over seven years found the recombinant vaccine was associated with a 9% overall decrease in cardiovascular burden, with a 10% decrease for ischemic heart disease and a 12% decrease for heart failure. The association faded somewhat over time.¹⁹

There’s also a growing body of evidence linking shingles vaccination to a lower risk of dementia. One study found that the recombinant vaccine was associated with a 17% increase in dementia diagnosis-free time, which translated to about 164 additional days lived without a dementia diagnosis among those who were eventually affected.²⁰

These findings are observational, not from randomized trials, so they could partly reflect the fact that people who get vaccinated tend to be healthier overall. Researchers have used statistical methods to try to control for that “healthy vaccinee” bias, but it can never be fully eliminated in this type of study. Still, there are plausible biological reasons why reducing viral reactivation might protect blood vessels and the brain, and the consistency of the signal across multiple studies and populations is hard to ignore. These potential bonuses aren’t the primary reason to get vaccinated, but they may eventually expand how we think about the vaccine’s value.

Does Childhood Chickenpox Vaccination Change the Equation

There’s been a long-running debate in public health about whether childhood chickenpox vaccination might inadvertently increase shingles rates in older adults. The logic goes like this: if fewer children are getting chickenpox, older adults who already carry the virus have fewer opportunities for a natural immune “boost” from being exposed to infected kids, and that reduced boosting could let the dormant virus reactivate more easily.

A systematic review that examined this question found no conclusive evidence that chickenpox vaccination has actually increased shingles rates at the population level. Shingles incidence had already been rising before childhood vaccination programs began. After implementation, the review found a net increase in shingles in only one age group (10 to 49 years), and even that was modest. The researchers noted that these findings don’t disprove the boosting theory, but they do suggest that the effect, if real, may be too small to detect at a population scale.²¹

For anyone wondering whether they still need the shingles vaccine if they never had chickenpox, or if they were vaccinated against chickenpox as a child: the chickenpox vaccine itself uses a live weakened form of varicella-zoster virus, which can also establish latency, so shingles is still possible in vaccinated individuals, though less common than after natural infection. As more chickenpox-vaccinated generations reach middle age, the role of Shingrix for this group will become an increasingly relevant question that the current data can only partially answer.

Who Should Think Twice and Who Should Not Wait

The U.S. CDC recommends Shingrix for all adults 50 and older, as well as for adults 19 and older who are immunocompromised. A few situations merit extra consideration:

• Previous shingles: You can and should still get vaccinated. Having had shingles once does not make you immune to future episodes, and recurrence is more common than most people realize.
• Previous Zostavax: If you got the older live vaccine, you should still get Shingrix. Zostavax’s protection was weaker and faded faster.
• Adults 50 to 54: The vaccine is approved and recommended, but the cost-effectiveness is less compelling at this age than at 60. If you have conditions that raise your risk, like diabetes, autoimmune disease, or chronic lung disease, the calculus tips more strongly in favor of earlier vaccination.
• Active shingles outbreak: Wait until the rash has resolved before getting vaccinated.
• Pregnancy: There is not enough safety data; vaccination is generally deferred.

If you’re over 60 with no contraindications, the case for Shingrix is about as clear-cut as preventive medicine gets. The disease is common, its complications can be severe, the vaccine works well, and the worst you’re likely to feel afterward is a rough day or two. The side effects are real, but they’re a short-term tax on a long-term benefit that goes well beyond preventing a rash.